Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RIGL 
Rigel Pharmaceuticals Inc (RIGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: RIGL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $38.33
1 Year Target Price $38.33
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.26% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 501.17M USD | Price to earnings Ratio 5.15 | 1Y Target Price 38.33 |
Price to earnings Ratio 5.15 | 1Y Target Price 38.33 | ||
Volume (30-day avg) 6 | Beta 1.2 | 52 Weeks Range 13.57 - 43.72 | Updated Date 10/18/2025 |
52 Weeks Range 13.57 - 43.72 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 36.51% | Operating Margin (TTM) 60.09% |
Management Effectiveness
Return on Assets (TTM) 39.01% | Return on Equity (TTM) 37.61% |
Valuation
Trailing PE 5.15 | Forward PE 4.87 | Enterprise Value 457063000 | Price to Sales(TTM) 1.87 |
Enterprise Value 457063000 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 4.18 | Shares Outstanding 17937340 | Shares Floating 16084772 |
Shares Outstanding 17937340 | Shares Floating 16084772 | ||
Percent Insiders 2.65 | Percent Institutions 79.39 |
Upturn AI SWOT
Rigel Pharmaceuticals Inc
Company Overview
History and Background
Rigel Pharmaceuticals, Inc. was founded in 1996. The company focuses on discovering and developing novel, small-molecule drugs for hematologic disorders, cancer, and immune diseases. Over the years, Rigel has partnered with larger pharmaceutical companies and focused on advancing its pipeline through clinical trials.
Core Business Areas
- Hematology/Oncology: Development and commercialization of therapies for blood disorders and cancers, with a focus on immune thrombocytopenia (ITP) and other hematologic malignancies.
- Immunology: Research and development of therapies targeting immune-related diseases, including autoimmune disorders and inflammatory conditions.
Leadership and Structure
Rigel is led by a management team with experience in drug development and commercialization. The organizational structure includes research and development, clinical operations, commercial operations, and corporate support functions.
Top Products and Market Share
Key Offerings
- Tavalisse (fostamatinib): Tavalisse is an oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. Competitors include thrombopoietin receptor agonists (TPO-RAs) like romiplostim (Nplate) from Amgen and eltrombopag (Promacta) from Novartis, as well as rituximab (Rituxan) from Genentech/Biogen. Market share is variable and influenced by pricing and clinical efficacy data.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and subject to regulatory oversight. The market for hematology and oncology drugs is growing due to an aging population and advancements in treatment options. Immunology is also experiencing growth due to increased understanding of immune-mediated diseases.
Positioning
Rigel positions itself as a specialized biopharmaceutical company focused on developing targeted therapies for niche markets within hematology, oncology, and immunology. Its competitive advantages include its expertise in kinase inhibitor development and its focus on unmet medical needs.
Total Addressable Market (TAM)
The total addressable market (TAM) for ITP and other targeted therapies is estimated to be in the billions of dollars. Rigel aims to capture a significant share of this market through continued commercialization efforts and pipeline development.
Upturn SWOT Analysis
Strengths
- Approved product (Tavalisse)
- Targeted therapeutic focus
- Experienced management team
- Strong intellectual property position
Weaknesses
- Reliance on a single approved product
- Limited financial resources compared to larger pharmaceutical companies
- Commercial execution challenges
- Pipeline risk associated with drug development
Opportunities
- Expanding indications for Tavalisse
- Advancing pipeline candidates
- Strategic partnerships and collaborations
- Acquisition or in-licensing of new assets
Threats
- Competition from established therapies
- Regulatory hurdles and delays
- Patent challenges
- Market access and reimbursement issues
Competitors and Market Share
Key Competitors
- AMGN
- NVS
- RHHBY
Competitive Landscape
Rigel competes with larger pharmaceutical companies in the hematology and immunology markets. Its advantages include its focus on niche indications and its expertise in kinase inhibitor development. Disadvantages include limited financial resources and commercial reach compared to its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the commercialization of Tavalisse and pipeline advancement.
Future Projections: Future growth depends on expanding Tavalisse sales and successful clinical trials for pipeline candidates. Analyst estimates require accessing real-time financial data sources.
Recent Initiatives: Recent initiatives include ongoing clinical trials, commercialization efforts for Tavalisse, and exploration of strategic partnerships.
Summary
Rigel Pharmaceuticals is a biopharmaceutical company focused on hematology and immunology. Their key strength lies in Tavalisse, but they face competition from larger firms. Future growth depends on successful expansion of Tavalisse and pipeline advancement. Financial stability is a key aspect to monitor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports and filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share percentages are estimates and may not reflect precise values.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rigel Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2000-11-29 | President, CEO & Director Mr. Raul R. Rodriguez | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | Website https://www.rigel.com |
Full time employees 162 | Website https://www.rigel.com | ||
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.